Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus

Authors: Taha Elmetwali, Peter F Searle, Iain McNeish, Lawrence S Young, Daniel H Palmer

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

CD40 and its ligand (CD40L) play a critical role in co-ordinating immune responses. CD40 is also expressed in lymphoid malignancies and a number of carcinomas. In carcinoma cells the physiological outcome of CD40 ligation depends on the level of receptor engagement with low levels promoting cell survival and high levels inducing cell death. The most profound induction of cell death in carcinoma cells is induced by membrane-bound rather than recombinant soluble CD40L, but like other TNF family ligands, it is cleaved from the membrane by matrix metalloproteinases.

Results

We have generated a replication-deficient adenovirus expressing a mutant CD40L that is resistant to metalloproteinase cleavage such that ligand expression is retained at the cell membrane. Here we show that the mutated, cleavage-resistant form of CD40L is a more potent inducer of apoptosis than wild-type ligand in CD40-positive carcinoma cell lines. Since transgene expression via replication-deficient adenovirus vectors in vivo is low, we have also engineered a conditionally replicating E1A-CR2 deleted adenovirus to express mutant CD40L, resulting in significant amplification of ligand expression and consequent enhancement of its therapeutic effect.

Conclusions

Combined with numerous studies demonstrating its immunotherapeutic potential, these data provide a strong rationale for the exploitation of the CD40-CD40L pathway for the treatment of solid tumours.
Appendix
Available only for authorised users
Literature
1.
van Kooten C, Banchereau J: CD40-CD40 ligand. J Leukoc Biol. 2000, 67 (1): 2-17.PubMed
2.
Eliopoulos AG, Young LS: The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 2004, 4 (4): 360-7. 10.1016/j.coph.2004.02.008CrossRefPubMed
3.
Challa A, Eliopoulos AG, Holder MJ, Burguete AS, Pound JD, Chamba A, Grafton G, Armitage RJ, Gregory CD, Martinez-Valdez H, Young L, Gordon J: Population depletion activates autonomous CD154-dependent survival in biopsy like Burkitt lymphoma cells. Blood. 2002, 99 (9): 3411-8. 10.1182/blood.V99.9.3411CrossRefPubMed
4.
Pham LV, Tamayo AT, Yoshimura LC, Lo P, Terry N, Reid PS, Ford RJ: A CD40 Signalosome anchored in lipid rafts leads to constitutive activation of NF-kappaB and autonomous cell growth in B cell lymphomas. Immunity. 2002, 16 (1): 37-50. 10.1016/S1074-7613(01)00258-8CrossRefPubMed
5.
Baxendale AJ, Dawson CW, Stewart SE, Mudaliar V, Reynolds G, Gordon J, Murray PG, Young LS, Eliopoulos AG: Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth. Oncogene. 2005, 24 (53): 7913-23. 10.1038/sj.onc.1208929CrossRefPubMed
6.
Bugajska U, Georgopoulos NT, Southgate J, Johnson PW, Graber P, Gordon J, Selby PJ, Trejdosiewicz LK: The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis. J Natl Cancer Inst. 2002, 94 (18): 1381-95.CrossRefPubMed
7.
Georgopoulos NT, Steele LP, Thomson MJ, Selby PJ, Southgate J, Trejdosiewicz LK: A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death Differ. 2006, 13 (10): 1789-801. 10.1038/sj.cdd.4401859CrossRefPubMed
8.
Davies CC, Mason J, Wakelam MJ, Young LS, Eliopoulos AG: Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells. J Biol Chem. 2004, 279 (2): 1010-9. 10.1074/jbc.M303820200CrossRefPubMed
9.
10.
Malemud CJ: Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 2006, 11: 1696-701. 10.2741/1915CrossRefPubMed
11.
Knox PG, Milner AE: Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand. J Immunol. 2003, 170 (2): 677-85.CrossRefPubMed
12.
Graf D, Muller S: A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol. 1995, 25 (6): 1749-54. 10.1002/eji.1830250639CrossRefPubMed
13.
Mazzei GJ, Edgerton MD, Losberger C, Lecoanet-Henchoz S, Graber P, Durandy A, Gauchat JF, Bernard A, Allet B, Bonnefoy JY: Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem. 1995, 270: 7025-7028. 10.1074/jbc.270.13.7025CrossRefPubMed
14.
Heise C, Hermiston T: An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med. 2000, 6 (10): 1134-9. 10.1038/80474CrossRefPubMed
15.
Afford SC, Randhawa S: CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface fas ligand expression and amplifies fas-mediated hepatocyte death during allograft rejection. J Exp Med. 1999, 189 (2): 441-6. 10.1084/jem.189.2.441PubMedCentralCrossRefPubMed
16.
Eliopoulos AG, Dawson CW: CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene. 1996, 13 (10): 2243-54.PubMed
17.
Eliopoulos AG, Davies C: CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol. 2000, 20 (15): 5503-15. 10.1128/MCB.20.15.5503-5515.2000PubMedCentralCrossRefPubMed
18.
Dyson N, Guida P: Adenovirus E1A makes two distinct contacts with the retinoblastoma protein. J Virol. 1992, 66 (7): 4606-11.PubMedCentralPubMed
19.
Fattaey AR, Harlow E: Independent regions of adenovirus E1A are required for binding to and dissociation of E2F-protein complexes. Mol Cell Biol. 1993, 13 (12): 7267-77.PubMedCentralCrossRefPubMed
20.
21.
Kelly TJ, Lewis AM: Use of nondefective adenovirus-simian virus 40 hybrids for mapping the simian virus 40 genome. J Virol. 1973, 12 (3): 643-52.PubMedCentralPubMed
22.
Flint SJ, Wewerka-Lutz Y: Adenovirus transcription. II. RNA sequences complementary to simian virus 40 and adenovirus 2DNA in AD2+ND1- and AD2+ND3-infected cells. J Virol. 1975, 16 (3): 662-73.PubMedCentralPubMed
23.
Wold WS, Deutscher SL, Takemori N, Bhat BM, Magie SC: Evidence that AGUAUAUGA and CCAAGAUGA initiate translation in the same mRNA region E3 of adenovirus. Virology. 1986, 148 (1): 168-80. 10.1016/0042-6822(86)90412-5CrossRefPubMed
24.
Benedict CA, Norris PS, Prigozy TI, Bodmer JL, Mahr JA, Garnett CT, Martinon F, Tschopp J, Gooding LR, Ware CF: Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2. J Biol Chem. 2001, 276 (5): 3270-8. 10.1074/jbc.M008218200CrossRefPubMed
25.
Wold WS, Doronin K, Toth K, Kuppuswamy M, Lichtenstein DL, Tollefson AE: Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr Opin Immunol. 1999, 11 (4): 380-6. 10.1016/S0952-7915(99)80064-8CrossRefPubMed
26.
Liu Y, Xia D: Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma. Cancer Gene Ther. 2005, 12 (2): 122-32. 10.1038/sj.cgt.7700757CrossRefPubMed
27.
Kikuchi T, Miyazawa N: Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells. Cancer Res. 2000, 60 (22): 6391-5.PubMed
28.
Tomihara K, Kato K: Gene transfer of CD40-ligand to dendritic cells stimulates interferon-gamma production to induce growth arrest and apoptosis of tumor cells. Gene Ther. 2008, 15 (3): 203-13. 10.1038/sj.gt.3303056CrossRefPubMed
29.
Gonzalez-Carmona MA, Lukacs-Kornek V, Timmerman A, Shabani S, Kornek M, Vogt A, Yildiz Y, Sievers E, Schmidt-Wolf IG, Caselmann WH, Sauerbruch T, Schmitz V: CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo. Hepatology. 2008, 48 (1): 157-68. 10.1002/hep.22296CrossRefPubMed
Metadata
Title
CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus
Authors
Taha Elmetwali
Peter F Searle
Iain McNeish
Lawrence S Young
Daniel H Palmer
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-52

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue

Research

The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia

Research

Differential expression of DKK-1 binding receptors on stromal cells and myeloma cells results in their distinct response to secreted DKK-1 in myeloma

Research

Down-regulation of the Nucleotide Excision Repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells

Research

Epidermal growth factor receptor regulates β-catenin location, stability, and transcriptional activity in oral cancer

Research

Coordination of glioblastoma cell motility by PKCι

Research

Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits